Amneal Pharmaceuticals
440 U.S. Highway 22 East
Suite 104
Bridgewater
New Jersey
08807
United States
Tel: 908-947-3120
Fax: 908-947-4146
Website: http://www.amneal.com/
275 articles about Amneal Pharmaceuticals
-
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
9/24/2018
Cantor Fitzgerald Global Healthcare Conference in New York, NY, on Monday, October 1, 2018 at 2:55 p.m. ET.
-
Amneal to Report Third Quarter 2018 Results on November 7, 2018
9/21/2018
Amneal Pharmaceuticals, Inc. announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018, prior to the open of the U.S. financial markets.
-
Nirmal Mulye, chief executive officer of Missouri-based Nostrum Laboratories, is looking to take over Martin Shkreli’s mantle of being the poster-boy for drastic drug price increases.
-
Amneal to Present at Upcoming Investor Conferences
8/31/2018
Amneal Pharmaceuticals (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA. Morgan Stanley 16th Annual Global Healthcare Conference at 11:05 a.m. ET on September 12, 2018 in New York, NY.
-
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
8/31/2018
Amneal Pharmaceuticals, Inc. today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena®
-
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
8/20/2018
Amneal Pharmaceuticals, Inc. announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals, Inc. (JSP), a New York-based pharmaceutical manufacturer of prescription tablet and capsule formulations. The agreement is effective March 22, 2019.
-
Amneal Announces Solid Second Quarter 2018 Financial Results
8/9/2018
GAAP Net Revenue of $414 Million; Adjusted Net Revenue of $462 Million on a Combined Company Basis
-
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
-
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
7/23/2018
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Potassium Chloride oral solution.
-
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
6/29/2018
Amneal Pharmaceuticals, Inc. announced that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of Judge Richard G. Andrews of the U.S. District Court, District of Delaware
-
Amneal to Report Second Quarter 2018 Results on August 9, 2018
6/29/2018
Amneal Pharmaceuticals, Inc. announced that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018
-
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary®
6/20/2018
Amneal Pharmaceuticals, Inc. announced that it has entered into a settlement agreement with Actavis Laboratories FL, Inc. and Actavis Pharma Inc. (collectively, "Actavis") resolving patent litigation related to Rytary® (carbidopa-levodopa).
-
Amneal to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
6/6/2018
-
Amneal Announces FDA Approval of Cyclophosphamide for Injection USP, Generic to Cytoxan®
5/30/2018
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Cyclophosphamide for Injection USP, the Company's AP-rated therapeutic equivalent to Cytoxan® 500 mg, 1 g and 2 g Single-Dose Vials. The Company expects to begin shipping product shortly.
-
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
5/23/2018
The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment.
-
Amneal Pharmaceuticals Celebrates Combination by Ringing Opening Bell at New York Stock Exchange
5/18/2018
Founders along with members of management will ring the opening bell at the New York Stock Exchange this morning at 9:30 a.m. ET.
-
Amneal Announces FDA Approval and Launch of Generic Welchol® (Colesevelam HCl) Tablets, 625 mg
5/17/2018
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received final U.S. Food and Drug Administration (FDA) approval for a generic version of Welchol® (colesevelam HCI).
-
Amneal Introduces First Generic for Mephyton® (Phytonadione) Tablets, 5mg
5/15/2018
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has launched Phytonadione Tablets.
-
Amneal Announces Actions to Streamline Operations and Capture Cost Synergies
5/11/2018
Company will close its Hayward, California-based facilities and operations.
-
Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.